Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA(TM) 360° Cardiac Catheter First-in-Human Feasibility Study

Stock Information for Pulse Biosciences Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pulse Biosciences Inc

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
Pulse Biosciences Announces Plans to Initiate a Rights Offering
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA(TM) Cardiac Clamp
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX(TM) Nanosecond Pulsed Field Ablation (nsPFA(TM)) Cardiac Catheter

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.